文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

超声引导挽救性近距离放疗再照射治疗局部复发前列腺癌的长期结果

Long-term results of a protocol-based ultrasound-guided salvage brachytherapy as re-irradiation for local recurrent prostate cancer.
PubMed 文献 · Radiother Oncol · 2020-06-25

这项研究评估了82例既往接受放疗后局部复发前列腺癌患者,采用超声引导挽救性脉冲剂量率近距离放疗(PDR-BT)的长期疗效。中位随访49个月,5年累积局部复发率为17.7%,低、中、高危组间无显著差异;无3级胃肠道晚期副作用,最常见晚期副作用为1-3级尿失禁(18.3%)和尿频/尿急(17.1%)。结论认为该方案有效且晚期毒性低。

要点

  • 5年累积局部复发率17.7%,低、中、高危组间无显著差异。
  • 无3级胃肠道晚期副作用,1-3级尿失禁和尿频/尿急发生率分别为18.3%和17.1%。
  • PDR-BT可作为既往放疗后局部复发前列腺癌的有效治疗选择。

核心结论

  • PDR挽救性近距离放疗对既往放疗后局部复发前列腺癌有效且晚期毒性低。
  • 挽救性近距离放疗是既往放疗后局部复发前列腺癌的有价值治疗选择。

研究设计与样本

  • 单臂研究,纳入82例既往放疗后局部复发前列腺癌患者,中位年龄69岁。
  • 既往治疗包括外照射放疗(43/82,52.4%)、前列腺切除加辅助放疗(24/82,29.3%)或近距离放疗(15/82,18.3%)。
  • 所有患者接受单纯挽救性间质脉冲剂量率近距离放疗(PDR-BT),分两段各30 Gy,总参考剂量60 Gy(EQD2=71.5 Gy-eq),单脉冲剂量0.6 Gy/h,24小时持续。
  • 中位随访49个月(范围12-129个月),终点包括累积局部复发率、无PSA生存、总生存及晚期毒性(Common Toxicity Criteria)。

主要发现

  • 5年总累积局部复发率为17.7%,低、中、高危组间无显著差异。
  • 低、中、高危组无PSA生存率分别为67.3%、70.4%、63.8%,组间差异边缘非显著。
  • 未观察到3级胃肠道晚期副作用。
  • 最常见晚期副作用为1-3级尿失禁(18.3%,15/82)和1-3级尿频/尿急(17.1%,14/82)。

关键数值与推荐

  • PDR-BT方案:两段各30 Gy,单脉冲剂量0.6 Gy/h,24小时持续,总参考剂量60 Gy(EQD2=71.5 Gy-eq)。
  • 5年累积局部复发率17.7%,低、中、高危组无显著差异。
  • 低、中、高危组无PSA生存率分别为67.3%、70.4%、63.8%,差异边缘非显著。
  • 1-3级尿失禁发生率18.3%(15/82),1-3级尿频/尿急发生率17.1%(14/82)。

临床怎么用

  • 对于既往放疗后局部复发前列腺癌,可考虑超声引导PDR挽救性近距离放疗。
  • 治疗前应评估既往放疗类型(外照射、前列腺切除加辅助放疗或近距离放疗)。
  • 需关注并监测晚期泌尿系统毒性(尿失禁、尿频/尿急),但3级胃肠道毒性未见。

局限性

  • 单臂研究,无对照组。
  • 样本量82例,中位随访49个月,部分患者随访时间较短(最短12个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To assess the long-term results of protocol-based ultrasound-guided salvage pulsed-dose rate brachytherapy in locally recurrent prostate cancer following previous radiation therapy. MATERIALS AND METHODS: A total of 82 patients (median age 69 years) with locally recurrent prostate cancer after previous external beam radiation therapy (43/82, 52.4%), prostatectomy and adjuvant radiation therapy (24/82, 29.3%) or brachytherapy (15/82, 18.3%) were treated with sole salvage interstitial pulsed-dose rate brachytherapy (PDR-BT). The treatment regimen consisted of two PDR-BT sections with 30 Gy (single pulse dose 0.6 Gy/h, 24 h per day) each up to a total reference dose of 60 Gy (EQD2 = 71.5 Gy-eq). The endpoints of the present analysis are cumulative local recurrence-rate, PSA-free survival, overall survival and the treatment-associated late toxicity according to the "Common Toxicity Criteria" with a median follow-up of 49 months (range, 12-129 months). RESULTS: The 5-y. overall cumulative local recurrence rate was 17.7% with no significant differences between low, intermediate and high-risk groups. Differences in PSA-free survival were marginally non-significant, at 67.3%, 70.4% and 63.8% for low, intermediate and high risk group, respectively. No grade 3 gastrointestinal late side effects have been observed. The most common late side effect was urinary incontinence grade 1-3 and urinary frequency/urgency grade 1-3 in 18.3% (15/82) and 17.1% (14/82) of patients, respectively. CONCLUSION: PDR salvage brachytherapy in local recurrent previously irradiated prostate cancer is efficient with low late toxicity. Salvage-brachytherapy represents a valuable therapeutic option for the treatment of previously irradiated locally recurrent prostate cancer.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Schönle N, Strnad V, Lotter M, et al. Long-term results of a protocol-based ultrasound-guided salvage brachytherapy as re-irradiation for local recurrent prostate cancer. Radiother Oncol. 2020. PMID: 32593646. doi:10.1016/j.radonc.2020.06.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。